<DOC>
	<DOCNO>NCT00051012</DOCNO>
	<brief_summary>The purpose study provide opportunity patient exhibit progressive disease receive placebo companion 93-04-11 study receive ONTAK . It also design determine effectiveness ONTAK Cutaneous T-cell Lymphoma ( CTCL ) patient whose tumor express CD25 .</brief_summary>
	<brief_title>Study ONTAK ( Denileukin Diftitox ) Previously Treated Cutaneous T-Cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Patient must previously enrol Protocol 930411 randomize placebo arm ; patient meet eligibility criterion protocol 930411 expression CD25 CTCL tumor cell . CTCL disease Stage Ia III . History le equal 3 previous therapy . Repeated use agent consider 1 therapy unless part different combination regimen . Only 1 prior combination cytotoxic chemotherapy regimen permit . Topical systemic steroid consider therapy . Patient must evaluable measurable disease . Lymph node involvement great LN2 . No CTCL involvement bone marrow . No significant pulmonary cardiac disease . No active CNS , kidney , liver disease . No systemic infection . ECOG performance status 0 1 . â€¢ The 930414 study long open subject previously enrol 930410 920401 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>